Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
25-3
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
25-3
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #35916
advertisement
Tang X
45
Showing records 1 to 25 |
Display all abstracts from
Tang X
128719
Retinal Vascular Fingerprints as Novel Biomarkers for Primary Angle Closure Disease Progression
Wang J
Ophthalmology science
2025; 5: 100848
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Zhou Y
NPJ digital medicine
2025; 8: 400
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
Chan PP
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
128719
Retinal Vascular Fingerprints as Novel Biomarkers for Primary Angle Closure Disease Progression
Han S
Ophthalmology science
2025; 5: 100848
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Nie H
NPJ digital medicine
2025; 8: 400
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
Zhang X
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Gong X
NPJ digital medicine
2025; 8: 400
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
Aung T
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
128719
Retinal Vascular Fingerprints as Novel Biomarkers for Primary Angle Closure Disease Progression
Mou D
Ophthalmology science
2025; 5: 100848
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
Chew PTK
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
128719
Retinal Vascular Fingerprints as Novel Biomarkers for Primary Angle Closure Disease Progression
Tang X
Ophthalmology science
2025; 5: 100848
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Dai M
NPJ digital medicine
2025; 8: 400
128719
Retinal Vascular Fingerprints as Novel Biomarkers for Primary Angle Closure Disease Progression
Shi D
Ophthalmology science
2025; 5: 100848
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Guo Z
NPJ digital medicine
2025; 8: 400
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
Congdon N
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Deng X
NPJ digital medicine
2025; 8: 400
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
Dada T
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
128719
Retinal Vascular Fingerprints as Novel Biomarkers for Primary Angle Closure Disease Progression
He M
Ophthalmology science
2025; 5: 100848
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Li M
NPJ digital medicine
2025; 8: 400
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
Fang SK
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
128719
Retinal Vascular Fingerprints as Novel Biomarkers for Primary Angle Closure Disease Progression
Guo C; Wang N
Ophthalmology science
2025; 5: 100848
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Liu Y
NPJ digital medicine
2025; 8: 400
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
He M
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
128031
A three-tier AI solution for equitable glaucoma diagnosis across China's hierarchical healthcare system
Sun L
NPJ digital medicine
2025; 8: 400
128168
Controversies, consensuses, and guidelines for acute primary angle closure attack (APACA) by the Asia-Pacific Glaucoma Society (APGS) and the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
Kim CY
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025; 0: 100223
«
1
2
»
Issue
25-3
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept